ReviewClinical and translational science2022

Alternatives to rifampicin: A review and perspectives on the choice of strong CYP3A inducers for clinical drug-drug interaction studies.

Jayaprakasam Bolleddula et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.